Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New immunotherapy company to pursue gamma delta cells
November 2016
SHARING OPTIONS:

LONDON—International investment group Abingworth recently announced its seeding of GammaDelta Therapeutics Ltd, a new immunotherapy company. Cancer Research Technology, King's College London and the Francis Crick Institute have also supported the new company. GammaDelta was founded on research from Prof. Adrian Hayday and Dr. Oliver Nussbaumer at King’s College London and the Francis Crick Institute, funded in part by Cancer Research UK. The research focuses on gamma delta cells, a unique, conserved population of lymphocytes that play a role in many immune responses and immunopathologies. GammaDelta will leverage this research to develop improved immunotherapies for cancer and possibly other diseases as well.
 
Raj Mehta, founder and interim CEO of GammaDelta, said: “We are delighted to have attracted the support of Abingworth to the founding and development of GammaDelta Therapeutics and will use the proceeds to help us advance our innovative programs into the clinic.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.